Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $5,999,250.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 75,000 shares of the company’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $79.99, for a total value of $5,999,250.00. Following the completion of the transaction, the director directly owned 701,477 shares of the company’s stock, valued at $56,111,145.23. The trade was a 9.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Liquidia Stock Performance

Shares of LQDA stock opened at $86.80 on Friday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12-month low of $16.82 and a 12-month high of $91.10. The business’s 50 day moving average is $73.31 and its two-hundred day moving average is $51.72. The company has a market capitalization of $7.72 billion, a P/E ratio of 620.04 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s revenue was up 4187.1% on a year-over-year basis. Analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently modified their holdings of LQDA. GSA Capital Partners LLP raised its position in shares of Liquidia by 63.6% in the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Liquidia in the 3rd quarter valued at about $1,536,000. State of New Jersey Common Pension Fund D purchased a new position in Liquidia in the 4th quarter worth approximately $709,000. WCG Wealth Advisors LLC boosted its holdings in shares of Liquidia by 98.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock worth $1,877,000 after purchasing an additional 26,957 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after purchasing an additional 52,671 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. BTIG Research upped their price objective on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Bank of America reissued a “neutral” rating and set a $79.00 target price (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. Oppenheimer set a $75.00 price target on shares of Liquidia in a research report on Friday, June 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $86.18.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).